Abstract
The big data derived from major international collaborations now makes it possible to validate findings from traditional national patient cohorts in order to demonstrate consistency. We compared findings from CBL-mutated patients in the Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) with those in the CMML cohort recorded in cBIOPORTAL. CBL mutations were linked to shorter survival in the ABCMML cohort but not in the cBioPortal cohort. In neither cohort was there an association between AML-free survival and CBL mutations. Elevated leukocyte levels were observed in patients with CBL mutations in both cohorts. In neither cohort did hemoglobin values, platelet values, and circulating blast levels differ between patients with CBL mutations and those without. Data validation using two independent CMML cohorts ensures the quality standards for clinical decision-making.